Pfizer (PFE) Stock
Fundamentals
Recent news

Why Pfizer Might Be the Most Underrated Dividend Stock to Buy Right Now
Why Pfizer Might Be the Most Underrated Dividend Stock to Buy Right Now
PFE

Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
PFE

Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation
Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation
PFE

Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
PFE
Technical indicators
- RSI 14
- 43.61
- MACD 12/26/9
- 0.10
- EMA 9 of MACD
- 0.23
- MACD histogram
- -0.13
- SMA 50
- $27.44
- Price above SMA 50
- EMA 50
- $27.44
- Price above EMA 50
- SMA 200
- $26.42
- Price above SMA 200
- EMA 200
- $26.50
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 6, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 6 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.70 for this quarter. The company has not yet shared when it is announcing earnings.
Latest news

Why Pfizer Might Be the Most Underrated Dividend Stock to Buy Right Now
Why Pfizer Might Be the Most Underrated Dividend Stock to Buy Right Now
PFE

Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
PFE

Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation
Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation
PFE

Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
PFE

Pfizer's Turnaround Could Be Bigger Than Investors Think, Set For 20% Upside
Pfizer's Turnaround Could Be Bigger Than Investors Think, Set For 20% Upside
PFE

Got $10,000 to Invest in October? These Stocks Could Generate Over $634 in Annual Income.
Got $10,000 to Invest in October? These Stocks Could Generate Over $634 in Annual Income.
PFE

Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?
Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?
PFE

Here's Exactly Why I'm Not Afraid of Pfizer's 6% Dividend Yield
Here's Exactly Why I'm Not Afraid of Pfizer's 6% Dividend Yield
PFE

My 3 Favorite Ultra-High-Yield Dividend Stocks to Buy for October
My 3 Favorite Ultra-High-Yield Dividend Stocks to Buy for October
PFE

3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note
3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note
PFE
About Pfizer
At Pfizer, we apply science and our global resources to bring therapies and healthcare products to people that extend and significantly improve their lives. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Albert Bourla D.V.M., Ph.D. | Chairman of the Board & CEO | 1962 |
| Dr. Chris Boshoff FMedSci, M.D., Ph.D. | Chief Scientific Officer and President of Research & Development | 1964 |
| Mr. Douglas M. Lankler | Executive VP & Chief Legal Officer | 1966 |
| Mr. Aamir Malik | Executive VP & Chief U.S. Commercial Officer | 1976 |
| Ms. Cecile Guegan | Interim CFO & Executive VP | 1971 |
| Ms. Jennifer B. Damico | Senior VP, Controller & Principal Accounting Officer | 1969 |
| Mr. Dennis P. Hancock | Executive VP & Chief Information Officer | — |
| Ms. Francesca M. DeMartino | Chief Investor Relations Officer | — |
| Ms. Payal Sahni Becher | Chief People Experience Officer & Executive VP | 1975 |
| Dr. Michael S. Vincent M.D., Ph.D. | Senior VP and Chief Scientific Officer of Inflammation & Immunology | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Technical indicators
- RSI 14
- 43.61
- MACD 12/26/9
- 0.10
- EMA 9 of MACD
- 0.23
- MACD histogram
- -0.13
- SMA 50
- $27.44
- Price above SMA 50
- EMA 50
- $27.44
- Price above EMA 50
- SMA 200
- $26.42
- Price above SMA 200
- EMA 200
- $26.50
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 6, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $26.00
- Average
- $29.67
- High
- $33.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +2.3 | +23.1 | +8.0 | |||||||||
| 2022 | -7.0 | -11.6 | +13.2 | -4.8 | +9.7 | +0.1 | -3.4 | -10.6 | -6.2 | +5.5 | +4.4 | +0.3 |
| 2023 | -13.9 | -7.7 | +1.5 | -5.9 | -3.0 | -3.5 | -1.6 | -0.6 | -7.3 | -10.0 | -0.1 | -0.4 |
| 2024 | -8.9 | -2.7 | +4.4 | -7.6 | +5.4 | -4.5 | +8.2 | -5.4 | +2.3 | -1.3 | -6.7 | +2.7 |
| 2025 | -0.3 | +0.9 | -3.5 | -0.5 | -1.8 | +3.3 | -7.0 | +5.4 | +2.0 | -9.4 | +4.4 | -1.5 |
| 2026 | +5.0 | +3.7 | +3.0 | -6.5 | -0.6 | -6.0 | +4.7 | +13.7 | -0.1 | -2.5 |
Corporate actions
Upcoming
No upcoming corporate actions for PFE



